Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 1282 Specimen Handling 927 Carboplatin 836 Magnetic Resonance Spectroscopy 834 Cyclophosphamide 807 Cisplatin 735 Nivolumab 680 Paclitaxel 635 Radiotherapy 617 Gemcitabine 580 Biopsy 559 Bevacizumab 485 Dexamethasone 444 fludarabine 410 Docetaxel 385 venetoclax 372 Oxaliplatin 367 Capecitabine 361 Fluorouracil 357 atezolizumab 350 durvalumab 340 Rituximab 335 Drug Therapy 333 Radiosurgery 321 Doxorubicin 319 Blood Specimen Collection 317 Standard of Care 311 Pemetrexed 307 Ipilimumab 303 Radiation 287

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

LY3300054 × 1 year × Clear all

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡